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Abstract
Background: Racial/ethnic differences for commonly measured clinical variables are
well documented, and it has been postulated that population-specific genetic factors
may play a role. The genetic heterogeneity of admixed populations, such as African
Americans, provides a unique opportunity to identify genomic regions and variants
associated with the clinical variability observed for diseases and traits across populations.
Method: To begin a systematic search for these population-specific genomic regions at
the phenome-wide scale, we determined the relationship between global genetic
ancestry, specifically European and African ancestry, and clinical variables measured in a
population of African Americans from BioVU, Vanderbilt University’s biorepository linked
to de-identified electronic medical records (EMRs) as part of the Epidemiologic
Architecture using Genomics and Epidemiology (EAGLE) study. Through billing
(ICD-9) codes, procedure codes, labs, and clinical notes, 36 common clinical and
laboratory variables were mined from the EMR, including body mass index (BMI),
kidney traits, lipid levels, blood pressure, and electrocardiographic measurements. A
total of 15,863 DNA samples from non-European Americans were genotyped on
the Illumina Metabochip containing ~200,000 variants, of which 11,166 were from
African Americans. Tests of association were performed to examine associations
between global ancestry and the phenotype of interest.
Results: Increased European ancestry, and conversely decreased African ancestry,
was most strongly correlated with an increase in QRS duration, consistent with
previous observations that African Americans tend to have shorter a QRS duration
compared with European Americans. Despite known racial/ethnic disparities in
blood pressure, European and African ancestry was neither associated with diastolic
nor systolic blood pressure measurements.
Conclusion: Collectively, these results suggest that this clinical population can be
used to identify traits in which population differences may be due, in part, to
population-specific genetics.
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Introduction
Racial/ethnic differences for commonly measured clinical variables, such as cholesterol
[1], body mass index [2], and hypertension [3], are well documented. Although the
causes of these observed differences are unclear, it has been postulated that population-
specific genetic factors may play a role [4]. The genetic heterogeneity of admixed popu-
lations such as African Americans provides a unique opportunity to identify genomic
regions and variants associated with the clinical variability observed for diseases and
traits across populations.
Previous studies have been primarily limited to genome-wide association studies
(GWAS) stratified by race/ethnicity (self-reported and/or genetic ancestry) and admix-
ture mapping studies of one or a handful of phenotypes in mostly epidemiologic collec-
tions. Both GWAS and admixture mapping studies offer the opportunity to identify
population-specific and trans-population associations involving specific genetic variants
or genomic regions. Other previous studies have directly tested for associations be-
tween race/ethnicity or genetic ancestry and specific phenotypes such as atrial fibrilla-
tion [5–7]. These latter studies offer the opportunity to identify and perhaps
distinguish between genetic and cultural or environmental factors that may account for
the differences in disease prevalence or incidence observed across populations. Despite
the success of these studies, no study has begun a systematic search of associations be-
tween genetic ancestry and traits phenome-wide.
Large epidemiologic and clinical collections often contain hundreds to thousands of
data points related to the health status of individuals. To begin a systematic search
for these population-specific genomic regions at the phenome-wide scale, we as the
Epidemiologic Architecture for Genes Linked to Environment (EAGLE) study deter-
mined the relationship between global genetic ancestry (percent European and African
ancestry) and clinical variables measured in an African American population from BioVU,
the Vanderbilt University biorepository linked to de-identified electronic medical records
[8, 9]. We describe here the distribution of global European and African ancestry and sig-
nificantly associated clinical traits among >11,000 African Americans from BioVU. Over-
all, these data suggest that systematic searches for relationships between genetic ancestry
and disease outcomes and traits have the potential to prioritize phenotypes with evidence
of strong population differences for further study.
Methods
Study population
The DNA samples and data described here are from Vanderbilt University’s BioVU, a
biorepository linked to de-identified electronic medical records. The establishment of
BioVU including the ethical and legal considerations has been described elsewhere [8, 10].
Briefly, BioVU is an opt-out clinical collection that includes DNA samples extracted from
discarded blood drawn for routine care at Vanderbilt University Medical Center out-
patient clinics. DNA samples are linked to a de-identified version of the patient’s elec-
tronic medical records known as the Synthetic Derivative. The Synthetic Derivative
contains structured, semi-structured, and unstructured clinical data that can be used
for research purposes. Race/ethnicity in BioVU is administratively assigned and has
been previously shown to be highly concordant with genetic ancestry for European
Americans and African Americans [11, 12].
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Genotyping
We as part of the EAGLE study accessed all DNA samples and data from non-
European Americans within BioVU as of 2011 for genotyping. These data are collect-
ively referred to here as “EAGLE BioVU” [9]. A total of 15,863 samples were targeted
for Illumina Metabochip genotyping. The Illumina Metabochip is a 200,000 variant array
designed for replicating genome-wide association study findings (index variants) and for fine
mapping select GWAS findings for cardiovascular and metabolic traits and outcomes [13].
The EAGLE BioVU dataset was generated by the Vanderbilt DNA Resources Core, and
genotype calls and quality control were performed by the Population Architecture using
Genomic and Epidemiology (PAGE) Coordinating Center as previously described [9, 14].
Phenotyping
We defined 36 phenotypes using a combination of billing (International Classification
of Diseases 9 or ICD-9) codes, procedure (CPT) codes, labs, and clinical notes available
in the Synthetic Derivative. All phenotypes described here were extracted for the gen-
etic association studies as part of the larger PAGE I study [15] and will be available via
dbGaP. Algorithms for body mass index [Goodloe R, Faber-Eger E, Boston J, Crawford
DC, Bush WS: Reducing clinical noise for body mass index measures due to unit and
transcription errors in the electronic medical record, in preparation]. electrocardiographic
traits (QRS duration, PR interval, QT interval, QRS, and heart rate) [16], and type 2 dia-
betes [17] have been previously described. The other phenotypes were defined as follows:
Lipids
 Laboratory measurements were queried for high-density lipoprotein cholesterol (HDL-C),
low density lipoprotein cholesterol (LDL-C), total cholesterol, and triglycerides.
 Records were also queried for calculated LDL-C.
 For each individual, median values were calculated for a) measurements taken
when no medications are prescribed (“pre-medication” values) and b)
measurements taken at first mention of medication and post mention of medication
(“post-medication” values)
 Medication class and list: statins (also known as HMG CoA reductase inhibitors,
atorvastatin (Lipitor®), fluvastatin (Lescol®), lovastatin (Mevacor®, Altoprev™),
pravastatin (Pravachol®), rosuvastatin calcium (Crestor®), simvastatin (Zocor®),
lovastatin + niacin (Advicor®), atorvastatin + amlodipine (Caduet®), and simvastatin +
ezetimibe (Vytorin™); selective cholesterol absorption inhibitors (ezetimibe (Zetia®));
resins (cholestyramine (Questran®, Questran® Light, Prevalite®, Locholest®, Locholest®
Light), colestipol (Colestid®), colesevelam Hcl (WelChol®)); fibrates (gemfibrozil (Lopid®),
fenofibrate (Antara®, Lofibra®, Tricor®, and Triglide™), clofibrate (Atromid-S)); and niacin.
Kidney traits
 Laboratory measures were queried for albumin (UABM), serum albumin (ALB),
urinary albumin (UAlb, AlbCnc), albumin/creatinine ratio (AlbCre, SUA/C),
creatinine from blood (Creat), creatinine from urine (URCRE, SUCrea, Creat1),
urea nitrogen blood (BUN), and uric acid.
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 For each individual, median values were calculated if more than one value was
available in the Synthetic Derviative.
Primary essential hypertension
 Case definition 1: Individuals on hypertensive medication (list under systolic and
diastolic blood pressure) and ICD-9 codes 401.* or mention of “high blood pressure”
or “hypertension” in problem list
 Case definition 2: individuals not on hypertensive medication (list under systolic
and diastolic blood pressure) and >140/90 systolic/diastolic blood pressure readings
 “Baseline” hypertension was defined as an individual’s hypertension status at first
clinical visit.
 “Lifetime” hypertension status was defined as an individual’s hypertension status
over the course of the clinical records available in the Synthetic Derivative.
Systolic and diastolic blood pressure
 Measurements for pregnant individuals were excluded.
 In-patient measurements were excluded.
 For each individual, “baseline” blood pressure measures represent the first systolic
and diastolic blood pressure mentioned in the Synthetic Derivative.
 For each individual, median values were calculated for a) measurements taken
when no medications are prescribed (“pre-medication” values) and b)
measurements taken at first mention of medication and post mention of medication
(“post-medication” values).
 Medications: angiotensin converting enzyme inhibitors, angiotensin receptor blockers,
beta blockers, non-dihydropyridine calcium channel blockers, dihydropyridine
calcium channel blockers, hydralazine, minoxidil, central alpha agonists, direct
renin antagonists, aldosterone antagonists, alpha antagonists, diuretics (thiazides,
K-sparing, and loop diuretics)
 Excluded medication: phentolamine, phenoxybenzamine
Type 2 diabetes related traits
 Laboratory measures were queried for glucose, glycated hemoglobin, and insulin.
 For each individual, median values were calculated if more than one value was
available in the Synthetic Derivative.
Statistical methods
EAGLE BioVU Metabochip genotype data as part of the PAGE I study were first sub-
jected to quality control, including the identification of genetic ancestry outliers via
EIGENSTRAT, through the PAGE I Coordinating Center [14]. We selected 7,655 un-
correlated SNPs from among the ancestry informative SNPs described by the PAGE I
Coordinating Center [14] assayed by the Illumina Metabochip to estimate global gen-
etic ancestry among administratively assigned African Americans in quality-controlled
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EAGLE BioVU genotype data using STRUCTURE v2.3.4 (K = 3) [18]. Data from 395
International HapMap samples represented CEU, YRI, and CHB/JPN were downloaded
from the International HapMap Project and included in STRUCTURE runs as prede-
fined parental clusters. Percent European ancestry was determined by STRUCTURE for
each individual and used as the independent variable in tests of association.
Tests of association were performed using logistic or linear regression for 36 outcomes
or traits where global ancestry was the independent variable. Primary essential hyperten-
sion (baseline and lifetime) and type 2 diabetes were binary outcomes; all other outcomes
were continuous. Similar to the high-throughput PheWAS pipeline proposed by the
PAGE I study [19], analyses were not adjusted for covariates. Also similar to the PAGE I
study PheWAS pipeline [19], all continuous traits were tested for an association as un-
transformed and transformed (1+ natural logarithm) variables. Analyses were performed
using SAS version 9.2 (Cary, NC) and R (version 3.2.0) in R Studio (version 0.99.441).
We estimated local ancestry using LAMP [20] for three fine-mapped regions on the
Metabochip representing the three strongest associations with global European ancestry
ranked by p-values from the tests of association: QRS duration, QT interval, and BMI.
For these three traits, we identified a GWAS-significant variant in the NHGRI GWAS
Catalog [21] that was assayed by the Metabochip and further fine-mapped by the Meta-
bochip. From this search, we identified SCN10A rs6801957 (QRS duration) [22],
NOS1AP rs12143842 (QT interval) [23–27], and FTO rs1558902 (BMI) [28]. We then
considered assayed genetic variants within a 50 kb window of each of these GWAS-index
variants (SCN10A chr3:38664112–38860101; NOS1AP chr1:160256929–160654852; FTO
chr16:52245615–52755879) for local ancestry estimation using LAMP assuming 10 gener-
ations with an alpha at 0.2 and 0.8 and with a recombination rate of 1.0x10−9. We tested
for associations between percent local European and African ancestry and each of the
three traits untransformed and transformed (1+ natural logarithm).
Results
EAGLE BioVU characteristics are given in Table 1. On average, most are female and
relatively young. The largest non-European descent group is African American (n =
11,166), consistent with Davidson County, Tennessee population characteristics based
on the 2010 US Census. The average individual in EAGLE BioVU had approximately
82 clinic visits and 147 ICD-9 codes available in his/her medical record.
For each African American in EAGLE BioVU, we estimated percent European global
genetic ancestry using 7,655 SNPs from the Metabochip and STRUCTURE. As expected,
Table 1 EAGLE BioVU characteristics (n = 15,863)
% female 63.35
Mean (±SD) age in years 37 ± 20.46
African American 73.06 %
Hispanic 10.87 %
Asian 7.12 %
Other race/ethnicity 8.95 %
Mean (range) clinical visits 81.8 (1 – 1,456)
Mean (range) ICD-9 codes 147.3 (1 – 3,617)
Demographic and summary clinical characteristics are given for the study population
Abbreviations: standard deviation (SD), international classification of diseases (ICD-9)
Dumitrescu et al. BioData Mining  (2015) 8:35 Page 5 of 15
the African American population in EAGLE BioVU represents a complex, two-way ad-
mixture event of European and African-descent populations (Figs. 1, 2 and 3). Percent
West African ancestry ranged from 0 % to 100 % with a mean of 81 % and interquartile
range of 12.7 % (Fig. 3). Percent European ancestry ranged from 0 % to 100 % with a
mean of 17.2 % and interquartile range of 12.8 %. The average percent European an-
cestry estimated here is consistent with other estimates for African Americans [5, 7].
Given that race/ethnicity is administratively assigned and not self-reported [11, 12], it
is possible that individuals at the extremes of the global genetic ancestry distribution
have been incorrectly assigned race/ethnicity. To explore this possibility, we extracted
country of origin data from the clinical notes of EAGLE BioVU [Farber-Eger E, Good-
loe R, Boston J, Bush WS, Crawford DC: Extracting country-of-origin from electronic
medical records for gene-environment studies as part of the Epidemiologic Architec-
ture for Genes Linked to Environment (EAGLE) study, in preparation]. Of the 1,159 in-
dividuals with less than 5 % European global genetic ancestry, only 44 had data on
country of origin. Of these 44, 25 individuals with less than 5 % European global gen-
etic ancestry have clinical notes with evidence that they are from African nations
(Burundi, Ethiopia, Ghana, Kenya, Malawi, Nigeria, Rwanda, Senegal, Somalia, Sudan,
Tanzania, and Uganda). Of the 114 individuals with >95 % European global genetic an-
cestry, only one individual had country of origin data (Haiti).
We then performed sex-combined tests of association using logistic or linear regres-
sion for 36 outcomes or traits where European global ancestry was the independent
variable (Table 2). Among the three binary outcomes considered, percent European an-
cestry was not associated with baseline hypertension (56 %; p = 0.21), lifetime hyperten-
sion (78 %; p = 0.39), or type 2 diabetes (12 %; p = 0.18). Among the remaining
continuous outcomes considered, only QRS duration was significantly associated with
percent European global genetic ancestry (p = 6.7x10-5, n = 837; Fig. 4). European ances-
try was not associated with blood pressure measurements, kidney traits, type 2 diabetes
Fig. 1 Genetic ancestry and EAGLE BioVU African Americans. Global genetic ancestry was estimated in 11,166
African Americans in EAGLE BioVU using 7,655 SNPs from the Illumina Metabochip and STRUCTURE assuming
K = 3. The STRUCTURE plot is anchored by 395 International HapMap Project samples (CEU in red, YRI in green,
and CHB/JPT in light blue)
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associated measures, or any of the lipid traits (Table 2; Fig. 4). When all continuous
traits were transformed, similar results were observed where only QRS duration was
significantly associated with European global ancestry (p = 9.15x10−5; Additional file 1:
Table S1).
We also performed sex-combined tests of association using logistic or linear regres-
sion for the same 36 outcomes or traits where African global ancestry was the inde-
pendent variable (Table 3; Additional file 1: Table S2). Like the European global
ancestry analyses (Table 2), the only significant association identified was for QRS
duration (p = 1.3x10−4; Fig. 5). The genetic effect for the association identified be-
tween African global ancestry and QRS duration (β = −7.45; standard error 1.93) was
similar in magnitude but opposite in direction compared with the association identi-
fied for European global ancestry (β = 7.98; standard error = 1.99; Table 2; Fig. 4).
Fig. 2 Distribution of percent European global ancestry among. African Americans in EAGLE BioVU. STRUCTURE
was used to estimate global genetic ancestry using 7,655 SNPs assayed on the Illumina Metabochip and
assuming K = 3. Plotted are the global European ancestry estimates for 11,166 African Americans in EAGLE
BioVU where the x-axis represents the % global European ancestry and the y-axis represents the % of the total
African American sample in EAGLE BioVU
Fig. 3 Distribution of percent African global ancestry among. African Americans in EAGLE BioVU. STRUCTURE
was used to estimate global genetic ancestry using 7,655 SNPs assayed on the Illumina Metabochip and
assuming K = 3. Plotted are the global West African ancestry estimates for 11,166 African Americans in EAGLE
BioVU where the x-axis represents the % global African ancestry and the y-axis represents the % of the
total African American sample in EAGLE BioVU
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Table 2 Outcomes tested for an association with global European ancestry in African Americans
from EAGLE BioVU
Outcome (n) % or mean (± SD) OR or β (95 % CI or SE) P-value
Hypertension, baseline (n = 6,422) 56 % 1.20 (0.90 – 1.59) 0.21
Hypertension, lifetime (n = 8,691) 78 % 1.23 (0.82 – 1.86) 0.32
Type 2 diabetes (n = 1,356) 12 % 1.32 (0.91 – 1.91) 0.15
Albumin (g/dL), serum (n = 8,094) 4.05 (0.51) −0.001 (0.04) 0.88
Albumin creatinine ratio (mg/mmol) (n = 1,210) 14.0 (861.10) −123.82 (176.60) 0.48
Albumin (mg/dL), urinary (n = 1,199) 16.7 (640.2) −36.35(131.80) 0.78
Blood urea nitrogen (mg/dL) (n = 10,111) 11.00 (13.55) −0.23 (0.93) 0.80
Body mass index (kg/m2) (n = 9,247) 27.25 (7.21) 0.74 (0.51) 0.15
Creatinine (mg/dL), serum (n = 10,288) 0.88 (1.99) 0.07 (0.13) 0.59
Creatinine (g/kg/day), urinary (n = 172) 70.00 (73.89) 23.05 (38.86) 0.55
Diastolic blood pressure (mm Hg), baseline (n = 10,025) 76.00 (15.68) 0.48 (1.07) 0.66
Diastolic blood pressure (mm Hg), post-medication
(n = 5,653)
79.00 (10.06) 0.29 (0.90) 0.75
Diastolic blood pressure (mm Hg), pre-medication
(n = 7,009)
75.00 (11.28) 0.38 (0.92) 0.68
Glucose (mg/dL) (n = 9,918) 96.00 (34.33) 0.04 (2.37) 0.99
Glycated hemoglobin (mg/dL) (n = 2,925) 6.30 (1.80) 0.07 (0.23) 0.75
HDL-C (mg/dL) (n = 5,096) 50.00 (16.99) −1.02 (1.65) 0.54
HDL-c (mg/dL) post-medication (n = 2,097) 47.75 (16.56) −2.95 (2.48) 0.23
HDL-C (mg/dL), pre-medication (n = 4,273) 51.00 (17.09) −0.91 (1.81) 0.61
Heart rate (beats per minute) (n = 783) 76.00 (11.14) −3.28 (2.67) 0.22
Insulin (IU/mL) (n = 343) 16.90 (74.36) −11.15 (24.38) 0.65
LDL-C (mg/dL), regardless of medication status 99.00 (35.18) −1.17 (3.42) 0.73
LDL-C (mg/dL), post-medication 96.00 (38.90) 4.95 (5.78) 0.39
LDL-C (mg/dL), pre-medication 105.00 (39.70) −3.20 (4.26) 0.45
PR Interval (msec) (n = 781) 159.00 (17.92) −0.12 (4.30) 0.98
QRS duration (msec) (n = 837) 82.00 (8.65) 7.98 (1.99) 6.7x10-5
QT interval (msec) (n = 783) 376.00 (27.84) 11.62 (6.66) 0.08
Systolic blood pressure (mm Hg), baseline (n = 10,025) 125.00 (22.54) −1.43 (1.54) 0.35
Systolic blood pressure (mm Hg), post-medication
(n = 5,653)
132.00 (16.03) 0.78 (1.43) 0.58
Systolic blood pressure (mm Hg), pre-medication
(n = 7,009)
123.00 (16.38) −0.0003 (1.34) 0.99
Total cholesterol (mg/dL), regardless of medication status
(n = 5,439)
175.00 (39.48) −1.65 (3.70) 0.65
Total cholesterol (mg/dL), post-medication (n = 2,150) 173.50 (44.22) 3.48 (6.58) 0.60
Total cholesterol (mg/dL), pre-medication (n = 4,642) 181.00 (44.86) −3.57 (4.55) 0.43
Triglycerides (mg/dL), regardless of medication status
(n = 5,269)
98.00 (69.46) 3.34 (6.61) 0.61
Triglycerides (mg/dL), post-medication (n = 2,115) 110.00 (74.07) 10.63 (11.07) 0.34
Triglycerides (mg/dL), pre-medication (n = 4,445) 97.00 (79.25) 2.00 (8.20) 0.81
Uric acid (mg/dL) (n = 2,465) 5.40 (2.18) 0.06 (0.29) 0.84
Tests of association were performed using logistic and linear regression between 36 outcomes and percent European
global genetic ancestry among African Americans in EAGLE BioVU (n = 11,166). Descriptive statistics as well as summary
statistics of all associations are shown for each outcome tested.
Abbreviations: odds ratio (OR), standard deviation (SD), standard error (SE)
Significant associations are bolded and italicized
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For the three most significant test of associations between global ancestry and the
outcomes and traits considered here (QRS duration, QT interval, and BMI; Table 2),
we estimated local ancestry using LAMP [20] in the three fine-mapped regions (SCN10A,
NOS1AP, and FTO) and tested for associations with local European and African ancestry.
In this sample of African Americans, the QT interval associated NOS1AP region had on
average the least European ancestry (16.7 %) compared with the BMI associated FTO re-
gion (23.6 %) and the QRS duration associated SCN10A region (24.6 %). None of the tests
of association between local ancestry and the three traits was significant at p < 0.05.
Discussion
We extracted 36 health outcomes and traits from de-identified electronic medical re-
cords of 11,166 African Americans in EAGLE BioVU and tested each of these pheno-
types for an association with percent European and percent African global genetic
ancestry. In sex-combined analyses, we identified a significant association between QRS
Fig. 4 Continuous outcomes tested for an association with global European ancestry in African Americans
from EAGLE BioVU. Tests of association were performed using linear regression between 33 continuous
outcomes and percent. European global genetic ancestry among African Americans in EAGLE BioVU. Plotted
are the –log10 of the p-value and the effect size (beta). Significant results are annotated in blue whereas non-
significant results are annotated in gray. The red line represents the significance threshold at p = 0.001
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Table 3 Outcomes tested for an association with global African ancestry in African Americans
from EAGLE BioVU
Outcome (n) % or median
(± SD)
OR or β (95 % CI
or SE)
P-value
Hypertension, baseline (n = 6,422) 56 % 0.81 (0.61 – 1.07) 0.14
Hypertension, lifetime (n = 8,691) 78 % 0.81 (0.54 – 1.21) 0.30
Type 2 diabetes (n = 1,356) 12 % 0.75 (0.52 – 1.08) 0.12
Albumin (g/dL), serum (n = 8,094) 4.05 (0.51) 0.02 (0.04) 0.67
Albumin creatinine ratio (mg/mmol) (n = 1,210) 14.00 (861.08) 0.01 (0.17) 0.95
Albumin (mg/dL), urinary (n = 1,199) 16.7 (640.2) 0.04 (0.16) 0.79
Blood urea nitrogen (mg/dL) (n = 10,111) 11.00 (13.55) 0.10 (0.90) 0.92
Body mass index (kg/m2) (n = 9,247) 27.25 (7.21) −0.81 (0.50) 0.10
Creatinine (mg/dL), serum (n = 10,288) 0.88 (1.99) −0.09 (0.13) 0.50
Creatinine (g/kg/day), urinary (n = 172) 70.00 (73.89) −23.54 (38.74) 0.54
Diastolic blood pressure (mm Hg), baseline (n = 10,025) 76.00 (15.68) −0.35 (1.05) 0.74
Diastolic blood pressure (mm Hg), post-medication
(n = 5,653)
79.00 (10.06) 0.01 (0.88) 0.99
Diastolic blood pressure (mm Hg), pre-medication
(n = 7,009)
75.00 (11.28) −0.37 (0.90) 0.68
Glucose (mg/dL) (n = 9,918) 96.00 (34.33) −0.22 (2.30) 0.92
Glycated hemoglobin (mg/dL) (n = 2,925) 6.30 (1.80) −0.15 (0.22) 0.49
HDL-C (mg/dL) (n = 5,096) 50.00 (16.99) 1.09 (1.60) 0.49
HDL-c (mg/dL) post-medication (n = 2,097) 47.75 (16.55) 2.74 (2.38) 0.25
HDL-C (mg/dL), pre-medication (n = 4,273) 51.00 (17.09) 1.43 (1.73) 0.41
Heart rate (beats per minute) (n = 783) 76.00 (11.14) 2.44 (2.58) 0.35
Insulin (IU/mL) (n = 343) 16.90 (74.36) 11.67 (24.25) 0.63
LDL-C (mg/dL), regardless of medication status 99.00 (35.18) 0.58 (3.31) 0.86
LDL-C (mg/dL), post-medication 96.00 (38.90) −6.00 (5.55) 0.28
LDL-C (mg/dL), pre-medication 105.00 (39.70) 3.52 (4.11) 0.40
PR Interval (msec) (n = 781) 159.00 (17.92) 0.56 (4.16) 0.89
QRS duration (msec) (n = 837) 82.00 (8.65) −7.45 (1.93) 1.3x10-4
QT interval (msec) (n = 783) 376.00 (27.84) −9.66 (6.45) 0.14
Systolic blood pressure (mm Hg), baseline (n = 10,025) 125.00 (22.54) 1.37 (1.50) 0.36
Systolic blood pressure (mm Hg), post-medication
(n = 5,653)
132.00 (16.03) −0.30 (1.40) 0.83
Systolic blood pressure (mm Hg), pre-medication
(n = 7,009)
123.00 (16.38) −0.06 (1.31) 0.96
Total cholesterol (mg/dL), regardless of medication status
(n = 5,439)
175.00 (39.48) −0.35 (3.57) 0.92
Total cholesterol (mg/dL), post-medication (n = 2,150) 173.50 (44.22) −5.40 (6.31) 0.39
Total cholesterol (mg/dL), pre-medication (n = 4,642) 181.00 (44.86) 0.73 (4.38) 0.86
Triglycerides (mg/dL), regardless of medication status
(n = 5,269)
98.00 (69.46) −5.70 (6.40) 0.38
Triglycerides (mg/dL), post-medication (n = 2,115) 110.00 (74.07) −15.64 (10.62) 0.14
Triglycerides (mg/dL), pre-medication (n = 4,445) 97.00 (79.25) −1.75 (7.93) 0.83
Uric acid (mg/dL) (n = 2,465) 5.40 (2.18) −0.01 (0.28) 0.97
Tests of association were performed using logistic and linear regression between 36 outcomes and percent African
global genetic ancestry among African Americans in EAGLE BioVU (n = 11,166). Descriptive statistics as well as summary
statistics of all associations are shown for each outcome tested.
Abbreviations odds ratio (OR), standard deviation (SD), standard error (SE)
Significant associations are bolded and italicized
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duration and both European and African ancestry albeit in opposite directions. Other
than QRS duration, no other outcome or trait was associated with European or African
ancestry in sex-combined analyses.
QRS duration is a cardiac conduction trait extracted from electrocardiograms. Nor-
mal QRS duration generally ranges from 70 to 100 milliseconds in most populations
[16]. Abnormal or prolonged QRS duration (>120 msec) is used in the diagnosis of
bundle branch block or ventricular rhythm. The significant association identified here
with European and African ancestry is consistent with previous observations that
African Americans tend to have a shorter QRS duration compared with European
Americans [16]. The lack of association between global ancestry and QT interval,
another cardiac conduction trait tested here, is consistent with a similar study in African
Americans from seven large population-based cohorts [25].
The present study had several limitations and strengths. A major limitation of this
study is that global ancestry as opposed to local ancestry was estimated for each indi-
vidual. The estimation of local ancestry will enable the identification of associations
Fig. 5 Continuous outcomes tested for an association with global African ancestry in African Americans
from EAGLE BioVU. Tests of association were performed using linear regression between 33 continuous
outcomes and percent. African global genetic ancestry among African Americans in EAGLE BioVU. Plotted
are the –log10 of the p-value and the effect size (beta). Significant results are annotated in blue whereas
non-significant results are annotated in gray. The red line represents the significance threshold at p = 0.001
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between phenotypes and specific genomic regions. However, estimation of local ances-
try requires computational resources and dense genome-wide data. This dataset was
limited to Metabochip data, which is dense only in fine-mapped regions and is sparse
in non-fine mapped regions of the genome. Given the uneven genome-wide coverage,
we were unable to confidently impute genome-wide data nor estimate local genetic an-
cestry at a genome-wide level for further study.
Despite these limitations, we did estimate local ancestry for three specific regions as-
sociated with three specific traits including QRS duration. In this sample of African
Americans, QRS duration was not associated with local ancestry estimates for the
SCN10A fine-mapped region. Variants in SCN10A have been associated with cardiac
conduction (PR interval, QRS duration, and QT interval) in multiple populations in-
cluding European-descent [22, 29–31] and Indian Asians [29]. For African Americans,
variants in SCN10A have been strongly associated with PR interval [32]. Although a
small GWAS in African Americans did not identify genome-wide significant associa-
tions between QRS duration and variants in SCN10A, the data suggest that the
GWAS-index variants identified in European and Indian Asian populations generalize
to African Americans with a similar genetic effect size and direction [33]. The lack of
association between local genetic ancestry at SCN10A and QRS duration may be due to
the fact that this locus is not responsible for the global ancestry signal detected here.
This negative finding coupled with the lack of powerful GWAS in African Americans
for QRS duration suggest that there may be other genetic variants and gene regions yet
to be associated with this cardiac conduction trait in this population.
Another potential limitation for this global ancestry PheWAS is sample size and
power. Overall, the sample size is moderate, with >11,000 African Americans with
health-related data available for study. For individual phenotypes, however, sample size
and power vary. The most powerful tests of association were limited to the laboratory
values or vital signs routinely collected by the clinic, such as total cholesterol and blood
pressure. However, even for these common measures, power may be adversely im-
pacted by imprecise phenotype efforts when extracting data from electronic medical re-
cords. For example, it is assumed but not known if laboratory measures such as the
lipid traits or type 2 diabetes traits were taken while the individual was fasting. Like-
wise, blood pressure measurements can be impacted by prescription medication non-
compliance and diurnal effects. While care is taken to account for these factors in the
phenotyping process, it is likely that all phenotypes extracted from electronic medical
records have some degree of unintended phenotypic heterogeneity that will impact stat-
istical power.
A major strength of this study is that it is one of the few large, clinical collections
available for admixed populations such as African Americans. BioVU continues to ac-
crue clinical data linked to DNA samples already collected as well as clinical data for
new DNA samples representing new patients entering the Vanderbilt University Medical
Center system. The accrual of these new data, samples, and eventually genetic data make
this a potentially powerful dataset for further research in genetics and health disparities.
Another major strength of the current study is electronic phenotyping using structured
and unstructured data available in the EMR. Most previous PheWAS in clinical popula-
tions with available EMR data have been limited to billing (ICD-9) codes [30, 34–36].
Here, we take full advantage of the richness of the EMR to define cases and controls for
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select binary traits as well as to extract laboratory values for consideration as outcome
variables. The specific variables for phenotyping and analysis in this PheWAS were chosen
based on anticipated downstream studies in PAGE I [15]. While 36 phenotypes represent
only a fraction of the phenome compared with a PheWAS based on ICD-9 codes, many
of the phenotypes considered here have not yet been explored in published PheWAS.
Also, limiting this PheWAS to 36 phenotypes reduces the number of statistical tests per-
formed, which in turn lessens the impact of multiple testing when interpreting statistical
significance of the results. The association observed between European global ancestry
and QRS duration at p = 6.7x10−5 survives correction for multiple testing even if a conser-
vative Bonferroni correction (p = 0.0014) is applied.
Conclusions
We estimated global genetic ancestry in an admixed population and systematically
searched for associations between European and African ancestry and clinical outcomes
and traits mined from electronic medical records. We identified a significant associ-
ation between European and African ancestry and QRS duration, and this association is
supported by the known epidemiology of this electrocardiographic trait in diverse pop-
ulations. Further general genomic discovery and study of local genetic ancestry are war-
ranted to identify specific genomic regions associated with clinical outcomes in diverse
populations.
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